stoxline Quote Chart Rank Option Currency Glossary
  
Amneal Pharmaceuticals, Inc. (AMRX)
5.46  0.01 (0.18%)    04-17 16:00
Open: 5.52
High: 5.52
Volume: 1,211,877
  
Pre. Close: 5.45
Low: 5.37
Market Cap: 1,685(M)
Technical analysis
2024-04-17 4:44:56 PM
Short term     
Mid term     
Targets 6-month :  7 1-year :  7.54
Resists First :  5.99 Second :  6.46
Pivot price 5.81
Supports First :  5.25 Second :  4.36
MAs MA(5) :  5.53 MA(20) :  5.87
MA(100) :  5.49 MA(250) :  4.19
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  9.9 D(3) :  10.7
RSI RSI(14): 40.7
52-week High :  6.46 Low :  1.58
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AMRX ] has closed above bottom band by 12.8%. Bollinger Bands are 4.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.52 - 5.56 5.56 - 5.59
Low: 5.3 - 5.34 5.34 - 5.37
Close: 5.41 - 5.47 5.47 - 5.52
Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Headline News

Tue, 16 Apr 2024
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine - Business Wire

Mon, 15 Apr 2024
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price - Simply Wall St

Mon, 15 Apr 2024
Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the ... - Yahoo Finance

Sun, 14 Apr 2024
714,890 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Phocas Financial Corp. - MarketBeat

Sun, 14 Apr 2024
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Increase in Short Interest - MarketBeat

Wed, 10 Apr 2024
Amneal to Report First Quarter 2024 Results on May 3, 2024 - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 309 (M)
Shares Float 123 (M)
Held by Insiders 59.7 (%)
Held by Institutions 29 (%)
Shares Short 2,400 (K)
Shares Short P.Month 1,830 (K)
Stock Financials
EPS -0.48
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.05
Profit Margin -3.6 %
Operating Margin 13.1 %
Return on Assets (ttm) 4.6 %
Return on Equity (ttm) -36.1 %
Qtrly Rev. Growth 1.2 %
Gross Profit (p.s.) 0
Sales Per Share 7.74
EBITDA (p.s.) 1.62
Qtrly Earnings Growth 0 %
Operating Cash Flow 346 (M)
Levered Free Cash Flow 304 (M)
Stock Valuations
PE Ratio -11.38
PEG Ratio -6.6
Price to Book value 91
Price to Sales 0.7
Price to Cash Flow 4.87
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android